• Japanese
  • Korean
  • Chinese
Cover Image

Alzheimer disease - new drugs, markets and companies


Alzheimer's disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future.

Considerable research is in progress to understand the pathomechanism of the disease and find a cure. The only drugs approved currently are acetylcholinesterase inhibitors but they do not correct the basic pathology of the disease, beta amyloid deposits and neurofibrillary tangles. Several new approaches emphasize neuroprotection as well.

Research in Alzheimer's disease still aims at elucidating the basic pathomechanisms. Animal models are important for research, particularly in testing some of the potential therapeutic approaches. There is considerable research in progress at the various centers, some of which is funded by the National Institute of Aging of the National Institutes of Health.

Over 300 different compounds are at various stages of development for the treatment of Alzheimer's disease. These are classified and described. There are non-pharmacological approaches such as vagal nerve stimulation and cerebrospinal fluid shunting, which are in clinical trials. Approximately 180 clinical trials are listed, of which 126 are still in progress and 54 were discontinued for various reasons.

Table of Contents

0. Executive Summary 17

1. Clinical Features, Epidemiology and Pathology 19

2. Diagnostic Procedures for Alzheimer Disease 103

3. Management of Alzheimer Disease 151

4. Research in Alzheimer Disease 187

5. Drug Discovery & Development for Alzheimer Disease 205

6. Markets & Finances of AD Care 335

7. Companies 353

8. References 509

Tables and Figures

Note: The Table of Contents has Been Edited for Brevity. For a Complete List of Tables and Figures Please Request a Free Sample.

Show More
Get Notified
Email me when related reports are published